Explaining primary health care pharmacy expenditure using classification of medications for chronic conditions

Background The Valencian Autonomous Community (Spain) has implemented a scheme of purchasing services with the participation of public and private providers. Five districts are managed using public¿private partnership. The financing model is capitation and inter-center invoice. The pharmaceutical be...

ver descrição completa

Detalhes bibliográficos
Autores: Vivas-Consuelo, David|||0000-0003-2945-7525, Guadalajara Olmeda, María Natividad|||0000-0002-5992-3446, Barrachina Martínez, Isabel|||0000-0003-3710-1190, De la Poza, Elena|||0000-0003-2303-0811, Trillo-Mata, José-Luis, Usó-Talamantes, Ruth
Formato: artículo
Fecha de publicación:2011
País:España
Recursos:Universitat Politècnica de València (UPV)
Repositorio:RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Idioma:inglés
OAI Identifier:oai:riunet.upv.es:10251/37258
Acesso em linha:https://riunet.upv.es/handle/10251/37258
Access Level:acceso abierto
Palavra-chave:Prescribed drugs
Pharmaceutical expenditure
Chronic condition
Risk adjustment
Capitation payments
ECONOMIA APLICADA
ECONOMIA FINANCIERA Y CONTABILIDAD
ECONOMIA, SOCIOLOGIA Y POLITICA AGRARIA
Control de costes en los sistemas de salud y servicios sociales públicos 10621 / M - Grado en gestión y administración pública 146
Descrição
Resumo:Background The Valencian Autonomous Community (Spain) has implemented a scheme of purchasing services with the participation of public and private providers. Five districts are managed using public¿private partnership. The financing model is capitation and inter-center invoice. The pharmaceutical benefits are not included in the per capita assignment. Objectives Modeling and explaining pharmacy expenditure using electronic prescriptions drug data. Methods A database of electronic prescription corresponding to 625,246 patients between November 2008 and October 2009 was used to run four linear models that explain the pharmaceutical expenditures. We take as dependent variable the neperian log of total pharmacy annual cost per patient in the primary health setting. The independent variables used combined demographics with revised classification in 18 chronic conditions obtained from the anatomical therapeutic chemical classification index (ATC). Results The retrospective model selected included: gender, pharmaceutical co-payment status and 8 dummy variables for the number of chronic conditions of each patient from 1 to 8 or more. The goodness-of-fit achieved is measured in R2 of 57%. Conclusions These models must be considered in the current capitation system for pharmaceutical budgeting in a primary care setting established at regional level, as is the case in the Valencian Autonomous Community. The use of diagnostics and information regarding hospital encounters appears to be a complementary option for refining models of capitation of pharmaceutical and total health expenditure.